Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health to Present Results of RNA-seq Biomarker Study at San Antonio Breast Cancer Symposium

Premium

Genomic Health will present results from its first biomarker study using next-generation sequencing at the San Antonio Breast Cancer Symposium in December, company officials said this week.

CEO Kim Popovits said during a call to discuss the company's third-quarter earnings this week that the study was one of 16 abstracts accepted for presentation at the annual conference.

The company said in August that it had completed the 130-patient transcriptome sequencing breast cancer study of formalin-fixed, paraffin-embedded tissue (CSN 8/9/2011).

A key goal of the study was to assess sequencing technology on FFPE tissue. Popovits said this week that the company believes the project "to be the first clinical outcomes study using fixed paraffin-embedded tissue with this new technology."

She said that the company has so far completed two "early clinical research studies" using paraffin-embedded tissue in more than 200 patients.

"We've developed the capability to do both mutation analysis and whole-transcriptome profiling, and we're now applying these capabilities in full clinical development," she said, though she did not elaborate.

The company believes that mutation analysis alone will not be sufficient in helping physicians guide cancer therapy and envisions RNA-seq as a crucial component of genomic medicine.

"We believe that in the future, physicians and patients will require a comprehensive genomic analysis — including specific mutations as well as gene expression — to better inform treatment decisions," Popovits said during the call.

She added that Genomic Health aims "to be the first company to provide a platform that combines whole-transcriptome profiling and mutation analysis for large clinical studies using fixed paraffin-embedded tissue to translate genomic data into actionable clinical tests."

The company plans to provide further detail on these activities "early in 2012," she said.

Genomic Health began implementing next-gen sequencing as part of its discovery pipeline just over two years ago and plans to eventually move its molecular diagnostic platform from quantitative RT-PCR to next-gen sequencing.

Brad Cole, Genomic Health's chief operating officer, said this week that "100 percent of the 'R'" in the company's R&D budget is currently dedicated to next-gen sequencing-based projects, "and more than half of the 'D'" beyond its existing PCR-based projects in breast and prostate cancer.

Next-gen sequencing "is a significant portion of our R&D line," Cole said, but did not provide further details.

The company spent a total of $9.6 million on R&D in the third quarter, a 17 percent increase over $8.9 million in the year-ago period.

The company reported total third-quarter revenues of $52.1 million, a 12 percent jump over $46.3 million in the comparable period of 2010.

Net income decreased 16 percent to $3.2 million from $3.7 million.

As of Sept. 30, Genomic Health held cash and cash equivalents of $38.3 million. Cash, cash equivalents, and investments in marketable securities totaled $87.4 million.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.